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Abstract
Cellular senescence suppresses cancer by irreversibly arresting cell proliferation. Senescent cells 
acquire a pro-inflammatory senescence-associated secretory phenotype. Many genotoxic 
chemotherapies target proliferating cells non-specifically, often with adverse reactions. In accord 
with prior work, we show that several chemotherapeutic drugs induce senescence of primary 
murine and human cells. Using a transgenic mouse that permits tracking and eliminating senescent 
cells, we show that therapy-induced senescent (TIS) cells persist and contribute to local and 
systemic inflammation. Eliminating TIS cells reduced several short- and long-term effects of the 
drugs, including bone marrow suppression, cardiac dysfunction, cancer recurrence and physical 
activity and strength. Consistent with our findings in mice, the risk of chemotherapy-induced 
fatigue was significantly greater in humans with increased expression of a senescence marker in T-
cells prior to chemotherapy. These findings suggest that senescent cells can cause certain 
chemotherapy side effects, providing a new target to reduce the toxicity of anti-cancer treatments.
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Introduction
Cellular senescence is a complex stress response whereby cells irreversibly lose the capacity 
to proliferate, accompanied by numerous changes in gene expression (1). Many potentially 
oncogenic insults induce a senescence response, which is now recognized as a potent tumor 
suppressive mechanism. Other senescence-inducing stimuli include radiation, genotoxic 
drugs, tissue injury and remodeling, and metabolic perturbations (2). Moreover, senescent 
cells accumulate with age in several vertebrate organisms (1), and their elimination can 
delay the onset of several age-associated disorders in mice (3, 4). Senescent cells most likely 
promote aging through the senescence-associated secretory phenotype (SASP): the increased 
expression and secretion of inflammatory cytokines, chemokines, growth factors and 
proteases (5).
Genotoxic and cytotoxic drugs are widely used as anti-cancer therapies. Most such agents 
target proliferating cells through distinct, cell cycle-dependent mechanisms (6). Their 
cytotoxicity for many types of dividing cells often leads to side effects, which include 
immunosuppression, fatigue, anemia, nausea, diarrhea and alopecia (7). Moreover, clinical 
studies of cancer survivors treated during childhood suggest that some chemotherapies 
causes a range of long-term side effects that resemble pathologies associated with aging, 
including organ dysfunction, cognitive impairment and secondary neoplasms (8).
Many chemotherapeutic drugs alter cellular states, including the induction of senescence, in 
cancer cells and the tumor microenvironment (9, 10). Therapy-induced senescence (TIS) can 
stimulate immunosurveillance to eliminate tumor cells, but can also be a source of chronic 
inflammation and drug resistance (11). Indeed, a recent study showed that treatment of 
breast cancer patients with anthracycline and alkylating agents durably induces cellular 
senescence and a SASP in a p16INK4a-dependent, telomere-independent fashion (12). 
Expression of the tumor suppressor p16INK4a increases with age and is a robust senescence 
marker in numerous mouse and human tissues (13, 14).
To more precisely assess the physiological effects of TIS in vivo, we used a recently 
described mouse model (p16-3MR) in which p16INK4a-positive senescent cells can be 
detected in living animals, isolated from tissues, and eliminated upon treatment with an 
otherwise benign drug (15). Using this approach, we determined the contribution of 
senescent cells to a variety of common short and long-term chemotherapy toxicities. 
Additionally, we used a senescence marker to assess the relationship between senescent cells 
and chemotherapy toxicity in human patients.
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Results
Chemotherapy-induced senescence
The anthracycline antibiotic Doxorubicin (Doxo) is used to treat several types of cancer in 
human patients. Doxo intercalates into DNA and prevents topoisomerase II from resealing 
the DNA double strand break, which the enzyme creates to relieve torsional stress (16). 
Doxo also promotes histone eviction from chromatin, evoking a DNA-damage response and 
promoting changes in the epigenome and transcriptome (17). Despite reports of Doxo-
induced senescence in cancer cells, little is known about how normal cells respond to Doxo.
We exposed mouse embryonic and dermal fibroblasts (MEFs and MDFs) to different doses 
of Doxo, and identified concentrations that inhibit cell proliferation (growth) (Fig. S1A and 
S1B). We selected 250 nM, a dose at which we observed a complete growth arrest without 
significantly reduced viability (Fig. S1B and not shown). MDFs treated with 250 nM Doxo 
showed a sharp rise in senescence-associated β-galactosidase (SA-β-gal) activity and strong 
decline in DNA synthesis, as determined by EdU incorporation (Fig. 1A and S1C). 
Senescence was further confirmed by elevated levels of mRNAs encoding p16INK4a and the 
SASP components IL-1α, IL-6, Mmp-3, Mmp-9, Cxcl-1, Cxcl-10 and Ccl20 (5) using qPCR 
(Fig. 1B), and elevated levels of p21 and reduced levels of LaminB1 and intracellular 
HMGB1 proteins (5, 18, 19) using western analyses (Fig. 1C). Doxo-induced senescent cells 
also harbored persistent DNA damage (20), as measured by 53BP1 foci (Fig. 1D and S1D). 
Importantly, Doxo induced a similar senescent phenotype, including expression of 
senescence markers and persistent DNA damage, in two human dermal fibroblast strains 
(HCA2 and BJ) (Fig. S1E–G and not shown).
Paclitaxel is another widely used chemotherapeutic agent that stabilizes microtubule 
polymers, thereby preventing their disassembly and causing an arrest of mitosis. Paclitaxel 
also induced senescence in mouse cells, as measured by reduced cell proliferation (Fig. 
S2A), increased SA-β-gal activity (Fig. S2B), elevated expression of p16INK4a and several 
SASP factors (IL-1α, IL-6, Mmp-3, Mmp-9, Cxcl-1, Cxcl-10, Ccl20), as well as reduced 
expression of laminB1 (Fig. S2C).
To determine the impact of TIS in vivo, we used our recently developed mouse model 
(p16-3MR), which contains functional domains of Renilla luciferase (LUC), monomeric red 
fluorescent protein (mRFP), and a truncated herpes simplex virus (HSV)-1 thymidine kinase 
(tTK) under control of the senescence-sensitive p16INK4a promoter (15). Because LUC 
allows the detection of 3MR-expressing cells, we followed the induction of senescent cells 
by bioluminescence using a range of Doxo concentrations (Fig. 1E). Acute toxicity 
(excessive weight loss, rough fur, inactivity) was evident at the highest dose (25 mg/kg). We 
therefore used a single dose of 10 mg/kg for subsequent experiments. This dose appears to 
be biologically effective in that it can induce an anti-tumor response and toxicity (e.g. 
myelosuppression) but is well below the maximally tolerated doses. For comparison, human 
patients receive 6–8 biologically effective doses of Doxo at 1.25 mg/kg (~50 mg/m2), and 
cumulative toxicity is observed at 12.5 mg/kg (~400 mg/m2). Interestingly, in accord with 
human studies (12), this Doxo dose caused a 3-fold increase in whole-body bioluminescence 
(Fig. 1E–F), regardless of sex. The magnitude of the increase in bioluminescence was 
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comparable to the increase in p16INK4a mRNA in different tissues, including skin, lung and 
liver (Fig. 1G). Different cell types were induced to senescence by Doxo treatment, as 
shown in the skin where keratinocytes, endothelial cells, and, to a lesser extent, fibroblasts 
and smooth muscle cells, were p21+ by immunostaining (Fig. S3A). Importantly, the 
bioluminescence and expression levels of p16INK4a, IL-6 and Cxcl-10 persisted for several 
weeks (Fig. 1H and S3B). Similar to our data using Doxo, three other chemotherapeutic 
agents, Paclitaxel, Temozolomide (TMZ) and Cisplatin, induced bioluminescence in 
p16-3MR mice (Fig. S3C–D). Paclitaxel, TMZ and Cisplatin also elevated p16INK4A 
expression in skin (Fig. S3E). These data indicate that cytotoxic chemotherapeutic agents 
with different mechanisms of action can induce senescence in primary cells in culture, and 
in different tissues and cell types in vivo.
Inflammation, bone marrow recovery and heart function
Acute and chronic inflammatory responses are major hurdles for the beneficial outcomes of 
many anti-cancer chemotherapies (21). Indeed, high local and systemic levels of 
chemotherapy-induced cytokines and chemokines are associated with short-, medium- and 
long-term side effects of the drugs.
Because senescent cells generated by Doxo and Paclitaxel activated a SASP, which includes 
inflammatory factors, we investigated the impact of these cells in Doxo-treated p16-3MR 
mice. Senescent p16INK4a-positive cells can be selectively eliminated from p16-3MR mice 
by treating the mice with ganciclovir (GCV); the tTK moiety of 3MR phosphorylates GCV, 
converting it to a toxic DNA metabolite that incorporates into mitochondrial DNA and kills 
cells by apoptosis (15). We treated p16-3MR mice with Doxo, followed by GCV treatment 5 
days later. GCV markedly reduced bioluminescence and the expression of p16INK4a in 
Doxo-treated animals (Fig. 2A–B and Fig. S4A). GCV also reduced the number of cells with 
DNA damage foci (Fig. 2C and S4B). As expected, Doxo increased the expression of SASP 
factor genes associated with inflammation in the lungs of p16-3MR mice treated with Doxo 
(Fig. 2B), many (but not all) of which declined 7 days after GCV treatment (Fig. 2B). Thus, 
removal of senescent cells was sufficient to reduce many of the Doxo-induced inflammatory 
cytokines and chemokines in the tissue. Secreted factors not affected by GCV might be due 
to their expression by p21+/p16INK4a− cells, or might be independent of senescence. We also 
detected a significant increase in serum levels of the cytokine IL-6 and chemokine Cxcl-1 in 
treated with Doxo, which were reduced by GCV (Fig. 2D–E). As expected, Doxo-treated 
MEFs also secreted higher levels of IL-6 and Cxcl-1 compared to vehicle-treated cells (Fig. 
S4C–D).
Acute and chronic inflammatory responses often result from impairment of the immune 
system after chemotherapy. Indeed, bone marrow suppression is a major limiting factor for 
the tolerance and efficiency of these therapies. To determine whether the inflammatory 
indicators in Doxo-treated mice were partly due to bone marrow suppression, we determined 
the number and distribution of bone marrow cells (BMC) after treatment of female mice. 
There was a slight but not significant reduction in the total number of BMCs 2 weeks after 
Doxo treatment, which was rescued upon elimination of senescent cells by GCV (Fig. S5A). 
We detected no differences in the percentages of Sca1+c-Kit+ (LSK) cells, hematopoietic 
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stem cells (HSCs; CD150+CD48−LSK cells) and hematopoietic progenitor cells (HPC;, 
lineage−Sca1−c-Kit+ cells), suggesting the Doxo regimen we used did not affect the number 
or ratio of BM HSCs and HPCs (Fig. S5B–D). Also, we observed no significant difference 
in blood cell counts, suggesting that the Doxo regimen we used induces only mild and 
transient myelosuppression (not shown).
We also measured HPC function by a colony-formation assay. Strikingly, the number of 
colony-forming unit (CFU)-GEMM (granulocyte, erythrocyte, monocyte, megakaryocyte) 
and CFU-GM (granulocyte, monocyte) cells was significantly reduced by Doxo treatment, 
but rescued upon elimination of senescent cells by GCV (Fig. 2F–G). This finding was 
confirmed by 2-week cobblestone-area-forming-cell (CAFC) assays, which measure the 
function of HPCs. The number of 2-week CAFCs was significantly decreased in BMCs 
isolated from Doxo-treated animals, but not from animals in which senescent cells were 
eliminated (Fig. 2H).
One major limitation to the Doxo dose that can be given to patients is cardiotoxicity, largely 
due to thickening of the left ventricle wall (22). Importantly, the Doxo dose used in our 
model was sufficient to induce cellular senescence in the heart, as measured by induction of 
p16INK4a and p21 expression (Fig. S6A–C). Interestingly, the majority of cardiac senescent 
cells were CD31+ endothelial cells and, to a lesser extent, fibroblast-like cells, but not 
cardiomyocytes (Fig. S6D–E and not shown). To evaluate heart function in mice treated with 
Doxo with or without the elimination of senescent cells, we used echocardiography. As 
expected, Doxo caused a decline in the fractional shortening (contraction) and ejection 
fraction (blood volume pumping capacity) (Fig. 2I–J). Strikingly, treatment with GCV 
almost completely prevented these declines (Fig. 2I–J). There was no effect of any of the 
treatments on heart rate (Fig. 2K). These findings indicate that senescent cells contribute to 
chemotherapy-induced cardiac dysfunction. Notably, the cardiac dysfunction was 
significantly detectable 4 weeks after Doxo treatment, but not earlier (Fig. S6F–G), 
suggesting that the persistence of senescent cells after chemotherapy is important for the 
cardiotoxicity.
Thus, upon elimination of senescent cells after Doxo-treatment, it was possible to reduce the 
burden of circulating inflammatory factors, promote the functional recovery of HPCs and 
preventing cardiac dysfunction, thus limiting the drug toxicity.
Cancer spread and relapse
Another important side effect of chemotherapy is cancer relapse. To study the consequence 
of eliminating senescent cells on cancer recurrence and spread, we used the breast cancer 
cell line MMTV-PyMT, which expresses the viral oncogene Polyoma middle-T antigen. 
When implanted into the mammary fat pad, MMTV-PyMT cells grow in situ and 
subsequently spread to distal tissues, preferentially the lung and liver (23). We used MMTV-
PyMT cells that express Firefly luciferase (FLUC), enabling us to monitor the cells in living 
animals by bioluminescence using a substrate distinct from that used to detect senescent 
cells in p16-3MR mice. Because these tumor cells do not express the p16-3MR transgene, 
we can distinguish the effects of chemotherapy on the tumor cells from the effects of normal 
cells induced to senesce by chemotherapy.
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We injected FLUC-expressing MMTV-PyMT cells into mammary fat pads of p16-3MR 
mice. Once tumors were palpable, we treated the mice with vehicles, Doxo+PBS or Doxo
+GCV. As expected, Doxo retarded or transiently arrested tumor growth, as indicated by an 
increase in mouse survival (Fig. 3A and S7A). After a 1–2 week dormancy period, primary 
tumors resumed growth, with similar kinetics in the Doxo+PBS and Doxo+GCV groups 
(Fig. S7A). However, mice in the Doxo+GCV group showed increased survival, which was 
independent of the size of the primary tumor (Fig. 3A and S7A). Strikingly, while a majority 
(~80%) of mice treated with Doxo+PBS developed metastasis in the lung and liver, 
detectable by FLUC, many fewer (20%) mice in the Doxo+GCV group developed 
metastases (Fig. 3B–C). Regrowth of the primary tumors and ulcerations at the primary 
tumor sites prevented us from determining a full survival curve of these animals. 
Nonetheless, the data show that the removal of senescent cells after chemotherapy can 
prevent or delay cancer relapse and spread to distal tissues.
Patients diagnosed with breast cancer are most commonly treated with surgery followed by 
adjuvant chemotherapy or targeted therapy. To mimic this regimen in mice, we surgically 
removed MMTV-PyMT tumors once palpable (Fig. S7B), then treated the animals with 
Doxo+PBS or Doxo+GCV. After a short latency period due to Doxo treatment, primary 
tumors recurred in all the mice (Fig. 3D). However, the kinetics of re-growth of the primary 
tumors depended on the type of treatment the mice received after resection (Fig. 3D and 
S7C). At the time of sacrifice, tumors from the Doxo+PBS group averaged 16 mm in 
diameter, while tumors from the Doxo+GCV group averaged only 10 mm, as reflected by 
significant differences in the tumor bioluminescence signals (Fig. 3D, and not shown). 
Consistent with our finding in the previous experiment, the number of mice with metastasis 
was substantially lower in the Doxo+GCV group compared to the Doxo+PBS group (Fig. 
3E). Moreover, mice from the Doxo+GCV group that did develop metastasis showed 
significantly fewer metastatic foci (Fig. 3F and 3G).
While Doxo treatment likely induces senescence in the implanted tumor cells, it is important 
to note that the GCV treatment removes only the senescent normal host cells. Thus, these 
data suggest that chemotherapy can promote tumor growth and metastasis by inducing the 
senescence of non-tumor cells.
To further prove that the removal of senescent cells, and not the GCV treatment per se, can 
delay cancer progression, we tested the effect of ABT-263, an anti-apoptotic inhibitor with 
selective toxicity for senescent cells (24). As expected, ABT-263 eliminated Doxo-induced 
senescent cells from p16-3MR mice (Fig. S8A). Moreover, mice that were injected with 
MMTV-PyMT cells followed by surgical removal of the tumors and treatment with a 
combination of Doxo and ABT-263 showed delayed tumor recurrence and metastasis, 
similar to the effects of GCV (Fig. S8B–C).
Chemotherapy-induced fatigue
Asthenia (severe fatigue) is a common and important side effect of cytotoxic chemotherapy. 
The causes of asthenia in cancer patients are usually multi-factorial, and chemotherapy-
induced fatigue can persist for long periods in patients with resolved cancer, well after the 
completion of chemotherapy (25). To determine whether senescent cells contribute to 
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reduced activity after chemotherapy, we monitored Doxo-treated p16-3MR female mice with 
or without senescent cells for running wheel activity in metabolic cages. As expected, mice 
ran mainly at night, and Doxo significantly reduced the time spent running during the 12-
hour nocturnal cycle (Fig. 4A). Strikingly, the elimination of senescent cells was sufficient to 
almost entirely rescue this decline in running activity (Fig. 4A). Because treatments with 
Doxo and GCV had no effect on activity and sleep during the day, we focused on the 12-
hour nocturnal cycle (Fig. 4A and S9A). During each nocturnal cycle, control mice ran an 
average of ~4000 m, whereas Doxo-treated mice ran ~2500 m; mice treated with Doxo plus 
GCV ran 3800 m, which is near the activity of control mice (Fig. 4B).
To confirm the beneficial effect of eliminating senescent cells on spontaneous activity and 
understand the nature of this chemotherapy-induced fatigue, we monitored mice before and 
after treatments for running patterns and strength. Using running wheels in standard cages, 
we confirmed that, while Doxo/PBS treated animals experienced a ~50% decline in running 
activity, the elimination of senescent cells by GCV or ABT-263 after the chemotherapy 
limited this reduction to ~20% (Fig. 4C and S9B). Similarly, the decline in strength due to 
Doxo treatment, as measured by grasping to the cage lid, was substantially rescued by the 
elimination of senescent cells (Fig. 4D). Paclitaxel-treated mice experienced similar deficits 
in activity and strength, which were partially rescued by GCV-mediated elimination of 
senescent cells (Fig. S9C–D). Moreover, the elimination of senescent cells from mice 
bearing breast cancer also substantially increased the running wheel activity of Doxo-treated 
mice 3 weeks after the cancer cell injections (Fig. S9E).
Reduced spontaneous activity can be due to altered metabolism or food intake. However, 
from measurements made in the metabolic cages, there was no significant difference in basal 
metabolic rate (RQ) between control and Doxo-treated mice, with or without senescent cells 
(Fig. S10A). Moreover, food intake was comparable among the four groups, suggesting that 
loss of appetite or nausea were not responsible for the effects of Doxo on activity, at least for 
the treatment regimen used in this study (Fig. 4E). Doxo caused substantial weight loss, 
which showed a trend toward rescue by GCV, but the differences were not significant (Fig. 
S10B).
To study the effects of senescent cells on chemotherapy-induced toxicity in humans, we 
employed a validated marker of in vivo senescence, p16INK4a expression in peripheral blood 
T cells (PBTL), which we previously showed correlates with the burden of senescence in 
both mice and humans (12, 26–28). We asked whether this marker of organismal burden of 
senescent cells measured prior to therapy correlated with subsequent risk of chemotherapy-
induced toxicity in a prospectively collected cohort of 89 women with breast cancer 
undergoing standard chemotherapy with curative intent. Patients received combinations of 
an anthracycline (60%), alkylating agent (89%) and/or taxane (95%), and most patients 
(92%) also received G-CSF (pegylated-filgrastim) to minimize treatment-related neutropenia 
(Supplementary Table S1). We determined the correlation between pre-chemotherapy PBTL 
p16INK4a expression and four endpoints: fatigue, neuropathy, any hematologic toxicity and 
any non-hematologic toxicity. We restricted our analyses to severe toxicity (grade III or 
grade IV); each of the four pre-specified endpoints occurred with the expected frequency in 
our sample (10–57%, Supplementary Table S2).
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To test for an association between a marker of in vivo senescence and chemotherapy toxicity, 
we analyzed the data in two standard ways. First, we compared the mean p16INK4a 
expression in patients who did or did not experience a given toxicity, and tested for 
significance using a non-parametric test (Wilcoxon Rank Sum). Second, we compared the 
incidence of a given toxicity in patients within the highest quartile of p16INK4a expression 
versus the lowest quartile of p16INK4a expression and estimated relative risk using a logistic 
regression model that accounted for patient age and other clinical features (Supplementary 
Table S2). We did not observe a correlation between PBTL p16INK4a and either aggregated 
endpoint (all hematologic toxicities or all non-hematological toxicities), which is not 
surprising given the heterogeneous nature of these complex and compound endpoints. PBTL 
p16INK4a measured prior to treatment was modestly higher in patients who developed severe 
chemotherapy-induced neuropathy (7.94 vs. 7.49, p=0.11), with the incidence of severe 
neuropathy increased in patients within the highest quartile of p16INK4a expression (9% vs 
0%). The association between p16INK4a and neuropathy was of borderline significance, 
which could reflect either a chance association or weak statistical power given the small 
number of patients that developed grade III/IV neuropathy. There was a significant 
association between severe fatigue and pre-treatment PBTL p16INK4a (7.93 vs 7.39, p=0.02). 
Since p16INK4a is measured on a log2-scale, this difference suggests mean p16INK4a 
expression is ~40% greater in patients that experienced fatigue. The incidence of severe 
fatigue in patients with the highest p16INK4a was 44%, versus 5% in patients within the 
lowest quartile of p16INK4a expression, reflecting a ~9-fold increase in the relative risk of 
fatigue (p=0.03). As these data were age-adjusted, this suggests an in vivo marker of 
senescence predicts toxicity independently of chronologic age. In accord with the murine 
findings (Fig. 4), these results suggest that the burden of senescent cells, estimated prior to 
therapy using PBTL p16INK4a, predicts a patient’s risk of developing fatigue from cytotoxic 
chemotherapy.
Discussion
Cellular senescence is an important tumor suppressive mechanism that efficiently protects 
long-lived organisms from developing cancer at a young age (1). We and others have 
suggested that the secretory phenotype associated with senescent cells (SASP) can serve 
several biological functions, either beneficial or deleterious (29). Among the deleterious 
effects, the accumulation and persistence of senescent cells, possibly due to decreased 
clearance and/or chronic induction, can disrupt tissue homeostasis and drive the onset or 
progression of a variety of pathologies (2). Senescent cells are generated by many types of 
cancer chemotherapies, and can potentially fuel many aspects of cancer progression (30).
Here, we show that four commonly used chemotherapeutic drugs can induce the persistent 
presence of senescent cells in normal non-cancerous tissues. Therapy-induced senescent 
(TIS) cells share several characteristics with cells induced to senesce by other stimuli, 
including persistent hypo-proliferation, elevated expression of p16INK4a, evidence of 
persistent DNA damage and transcriptional activation of genes encoding many SASP factors 
(5, 20). Since the SASP is thought to fuel the development of a variety of diseases, 
particularly pathologies associated with chronic inflammation (1, 2), we investigated the 
effects of senescent cells induced in non-cancerous tissue by chemotherapy.
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Many chemotherapies have short-, medium- and long-term side effects, which often limit 
dosages, that require discontinuation of the treatment and/or reduce overall efficacy. 
Moreover, studies of cancer survivors show that one long-term effect of chemotherapy is the 
accelerated development of a host of age-associated diseases (8). We show that TIS cells 
contribute to local and systemic inflammation, as determined by increased expression of 
pro-inflammatory SASP factors in tissue and increased levels of inflammatory cytokines in 
sera, which is reduced after removal of senescent cells in vivo using p16-3MR transgenic 
mice. Further, the elimination of senescent cells limited or prevented the development of 
multiple adverse reactions to chemotherapy. In addition, weeks after chemotherapy 
treatment, TIS cells were important for bone marrow suppression and development of 
cardiac dysfunction, both limiting factors for the use of some chemotherapeutic agents, 
particularly the anthracyclines. The promotion of cardiac dysfunction might be due to either 
cardiac senescent cells, which we show are primarily endothelial cells, or senescence-
induced inflammation. Senescent non-tumor cells were important for cancer relapse and 
spread to distal tissues after chemotherapy, at least in the breast cancer model we used. 
Moreover, clearing senescent cells increased overall spontaneous physical activity in the 
presence or absence of cancer. Importantly, these murine findings were validated in a human 
cohort, showing that p16INK4a expression in peripheral T-cells predicts chemotherapy-
induced fatigue in human patients with breast cancer. We believe this latter finding is 
consistent with recent work showing that aging is the major risk factor for long-term (> 2 or 
>5 years) fatigue after chemotherapy treatment (25).
A limitation of our study relates to the conversion of drug dosing in humans and mice. Drug 
pharmacokinetics and pharmacodynamics differ significantly between rodents and humans, 
and a potential concern of these results is that senescence induction in vivo results from 
pharmacologically unrealistic doses in mice, as opposed to those used in humans. 
Considering our results in pharmacodynamic rather than pharmacokinetic terms, however, 
we note that the murine experiments used doses of these compounds induce a biologic effect 
(tumor reduction, myelosuppression, etc) but are sub-lethal. This is precisely the way such 
agents are used in humans; that is, at doses near the maximally tolerated dose that induce 
tumor response as well as cytoxicity (e.g. myelosuppression). Therefore, it seems reasonable 
to infer that a pharmacologically active dose in either species causes the accumulation of 
senescent cells in vivo. Additionally, we showed these effects in mice with multiple 
compounds, suggesting the accumulation of senescent cells in response to DNA damaging 
agents appears to be a general property of cytotoxicity chemotherapy administered at a 
biologically effective does, and not parochial to one of the compounds studied. Finally, we 
believe these results are in line with other results suggesting that cytotoxic chemotherapy 
induces senescence in humans (10, 12, 27, 31). In aggregate, we believe these results show 
that a variety of DNA damaging agents potently and rapidly increase the in vivo burden of 
senescent cells in humans and mice, and the accumulation of such cells causes long-term 
toxicity for the host.
Since many cytokines, chemokines, proteases and growth factors that comprise the SASP 
(5), it was conceivable that senescent cells might contribute to several side effects associated 
with cancer treatments. The data presented here show a direct role for TIS cells in mice, and 
a strong correlation between fatigue and senescent cells in humans. An alternative approach, 
Demaria et al. Page 9
Cancer Discov. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
then, is to develop therapies that can selectively target senescent cells (senolytics) and/or the 
SASP, an approach that recently showed promise (24). Indeed, the administration of a 
senolytic agent, ABT-263, efficiently eliminated senescent cells, improved physical activity, 
and reduced cancer relapse in mice treated with Doxo. Such therapeutic approaches will, of 
course, need to carefully consider whether there are beneficial effects of TIS, such as 
promoting the repair of tissues damaged by the chemotherapy or the potential of senescent 
cells to activate the immune response to tumor cells. Nonetheless, the pharmacological 
removal of senescent cells from the tumor microenvironment might be an innovative strategy 
to limit toxicities of current chemotherapies with consequent improvements in the health 
span and possibly life span of cancer patients.
Materials and Methods
Cell preparation and culture
13.5 day embryos were dissected and cultured to produce MEFs, and fibroblasts were 
derived from the dorsal skin of 3 mo old mice, as described (15). Primary mouse cells were 
expanded for no more than 10 doublings. Human fibroblasts HCA2 were obtained from O. 
Pereira-Smith (University of Texas Health Science Center, San Antonio). Cells were not re-
authenticated by the laboratory, but regularly monitored for mycoplasma contaminations 
(once/2 weeks). All cells were cultured in 3% oxygen for at least 4 doublings prior to use. 
MMTV-PyMT cells were purchased from ATCC (Manassas VI, USA), which validate cell 
lines by Short Tandem Repeat profiling, transduced with lentiviruses expressing Firefly 
Luciferase (fLUC) (Perkin Elmer, Akron OH, USA), and used for no more than 6 months 
after purchase. Doxorubicin hydrochloride and Paclitaxel (Sigma Aldrich, St Louis MO, 
USA) were dissolved in DMSO at 100 mM and diluted in serum-containing medium. Cell 
viability was assessed using the MTS assay (Promega, Madison WI, USA) according to the 
manufacturer’s protocol.
Mice
p16-3MR mice (15) were maintained in the AALAC-accredited Buck Institute for Research 
on Aging (Novato, CA, USA) animal facility. All procedures were approved by the 
Institutional Animal Care and Use Committee. p16-3MR mice were bred in-house. For in 
vivo luminescence and tissue extraction, both male and female mice were used. For all the 
other experiments, female mice were used. For Doxo treatments, 10–16 wk old p16-3MR 
mice were injected intraperitoneal (i.p.) once with 2, 10 or 25 mg/kg of doxorubicin 
hydrochloride (Sigma Aldrich) in PBS, and treated 5 d later with vehicle or GCV. GCV was 
administered via daily i.p. injections for 5 consecutive days at 25 mg/kg in PBS. Control 
mice were injected with an equal volume of PBS. For Paclitaxel treatments, 10–16 wk old 
p16-3MR mice were injected 3 times i.p. with 10 mg/kg of Paclitaxel (Sigma Aldrich) in 
PBS/5% DMSO, and treated 5 days later with vehicle or GCV. GCV was administered via 
daily i.p. injections for 5 consecutive days at 25 mg/kg in PBS. Control mice were injected 
with an equal volume of PBS. For Temozolomide treatments, 10–16 wk old p16-3MR mice 
were injected 3 times i.p. with 50 mg/kg (Sigma Aldrich) in PBS/5% DMSO/0.1% Tween. 
For Cisplatin treatments, 10–16 wk old p16-3MR mice were injected 3 times i.p. with 2.3 
mg/kg (Enzo Life Sciences, Farmingdale NY, USA) in PBS/1% DMSO.
Demaria et al. Page 10
Cancer Discov. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MMTV-PyMT-fLUC cells (105) were injected into the inguinal mammary fat pad. Surgical 
removal was done under total body anesthesia (isofluorane), and wounds were closed with 
metal stitches. Analgesia was injected subcutaneously pre-surgery and up to 48 hours post-
surgery (buprenorphine).
Real Time-PCR
Total RNA was prepared using the PureLink Micro-to-Midi total RNA Purification System 
(Life Technologies, Grand Island, NY, USA). RNA was reverse transcribed into cDNA using 
a kit (Applied Biosystems, Carlsbad CA, USA). qRT-PCR reactions were performed as 
described (15) using the Universal Probe Library system (Roche, South San Francisco CA, 
USA). Primer/probe sets for human and mouse p16, LmnB1, IL-1a, IL-6, Mmp-3, Mmp-9, 
Cxcl-1 were as previously reported (15, 32). Additionally, the following sets were used: 
Cxcl-10 Forward 5′-gctgccgtcattttctgc-3′, Reverse 5′-tctcactggcccgtcatc-3′, Probe #3; 
Ccl-20 Forward 5′-aactgggtgaaaagggctgt-3′, Reverse 5′-gtccaattccatcccaaaaa-3′, Probe 
#73; Ccl-7 Forward 5′-ttctgtgcctgctgctcata-3′, Reverse 5′-ttgacatagcagcatgtggat-3′, Probe 
89.
Bio-luminescence
For in vivo luminescence of Renilla Luciferase, mice were injected i.p. with 15 ug of 
Xenolight RediJect Coelentarazine h (Calipers/Perkin Elmer, Waltham MA, USA). 25 min 
later, the mice were anesthesized with isofluorane and luminescence measured with a 
Xenogen IVIS-200 Optical imaging System (Caliper Life Sciences, Hopkinton MA, USA; 5 
min medium binning). For in vivo luminescence of Firefly Luciferase, mice were injected 
i.p. with 150 mg/kg of Xenolight D-Luciferin (Calipers/Perkin Elmer). 5 min later, the mice 
were anesthesized with isofluorane and luminescence measured with a Xenogen IVIS-200 
Optical imaging System (Caliper Life Sciences; 3 min medium binning).
Immunoblot analysis
Cells were washed with warm PBS, lysed, and subjected to SDS–PAGE using 4–12% Bis-
Tris gels; separated proteins were transferred to nitrocellulose membranes (18). Membranes 
were blocked and incubated for 2 hrs at room temperature (LaminB1: Santa Cruz 
Biotechnology, Santa Cruz CA, USA; HMGB1: Abcam, Cambridge MA, USA) or overnight 
at 4° C (p21: Calbiochem, San Diego CA, USA; actin: Sigma-Aldrich) with primary 
antibodies. Membranes were washed and incubated with horseradish peroxidase (1:5000; 
Cell Signaling)–conjugated secondary antibodies for 45 min at room temperature and 
washed again. Signals were detected by enhanced chemiluminescence.
Enzyme-linked immunosorbent assays (ELISA)
ELISA kits to detect IL-6 and CXCL-1 were from R&D Systems (Minneapolis, MN, USA) 
and used according to the manufacturer’s protocols. Conditioned media were prepared by 
washing cells with serum-free DMEM and incubating in serum-free DMEM for 24 hours. 
For Doxo-treated cells, media was collected 10 days after treatment. ELISA results were 
normalized to cell number. Mouse sera was isolated by centrifugation.
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Immunofluorescence
Cells or OCT-embedded lungs on glass coverslips were washed in PBS, fixed in 4% 
paraformaldehyde, quenched with 50 mM glycine, permeabilized with 0.3% Triton X-100 in 
PBS, saturated with 3% goat serum (Life Technologies, Carlsbad CA, USA), and incubated 
with 53bp1 and γH2AX primary antibodies at room temperature (Novus Biologicals, 
Littleton CO, USA) for 1 hour, followed by incubation with Alexa fluorescein-labeled 
secondary antibodies (Life Technologies) for 45 minutes and mounted using Prolong Fade 
with Dapi (Life Technologies).
Metabolism and activity
p16-3MR mice were individually housed for 3 days prior to being transferred to an isolated 
room and monitored using a Promethion system (Sable Systems, North Las Vegas NV, USA) 
for 4 consecutive days. Alternatively, after 3 days of acclimation to single housing, mice 
were transferred to cages enriched with a running wheel (Columbus Instruments, Columbus 
OH, USA) and measured for 3 nights. Food intake was measured by weighting the chow 
every 24 hours. For grip strength, individual mice were trained for 3 trials and then grasping 
time measured over a subsequent 3 trials and averaged.
Collection of bone marrow cells (BMCs)
The femora and tibiae were harvested from mice immediately after they were euthanized 
with CO2. BMCs were flushed from the bones into HBSS containing 2% FCS using a 21-
gauge needle and syringe. The total number of BMCs harvested from the two hind legs of 
each mouse was determined after red blood cells were lysed.
Analysis of the frequencies of hematopoietic cell populations by flow cytometry
BMCs were preincubated with biotin-conjugated anti-CD3e, anti-CD45R/B220, anti-Gr-1, 
anti-CD11b and anti-Ter-119 antibodies and with anti-CD16/32 antibody to block the Fcγ 
receptors. They were then stained with streptavidin-FITC and anti-Sca1-PE-Cy7, c-Kit-
APC-Cy7, CD150-APC and CD48-Pacific blue. The frequencies of HPCs (Lin−Sca1−c-kit+ 
cells), LSK cells (Lin−Sca1+c-kit+ cells) and HSCs (CD150+CD48−LSK cells) were 
analyzed with an Aria II cell sorter. For each sample, approximately 5x105 – 1x106 BMCs 
were acquired and the data analyzed using BD FACSDiva 6.0 (BD Biosciences) and FlowJo 
(FlowJo, Ashland, OR) software.
Colony-Forming Cell (CFC) and Cobblestone Area-Forming Cell (CAFC) assays
The CFC assay was performed by culturing BM-MNCs (mono-nuclear cells) in MethoCult™ 
GF M3434 methylcellulose medium (Stem Cell™ Technologies Inc, Vancouver, Canada). 
Colonies of CFU-granulocyte macrophage (GM) were scored on day 7, and colonies of 
CFU-granulocyte, -erythrocyte, -monocyte and -megakaryocyte (GEMM) were scored on 
day 12 of the incubation, according to the manufacturer’s protocol. Cobblestone area-
forming cell (CAFC) assay was performed as described (24).
Demaria et al. Page 12
Cancer Discov. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Echocardiography
Two-dimensional transthoracic echocardiography was performed as described (29). In brief, 
mice were lightly anesthetized using 1.5% isoflurane mixed with 100% O2 during the time 
of imaging. Echocardiography was performed prior to and following the 4 week 
experimental period using a LZ 550 series, 55MHz MicroScan transducer probe and a Vevo 
2100 Imaging System (VisualSonics; Toronto, Ontario, Canada) (33). Left ventricular 
fractional shortening and ejection fraction were determined from the M-mode of the 
parasternal short-axis view. All parameters were averaged from at least 3 consecutive high-
resolution cardiac cycles for analysis.
Patients
This study, LCCC 1027, was conducted with consenting adult patients undergoing treatment 
for breast cancer at University of North Carolina (UNC) Hospitals, and approved by the 
UNC Institutional Review Board and registered on clinicaltrials.gov (NCT01305954). The 
study was conducted in accordance with the Declaration of Helsinki. Patients over the age of 
18 diagnosed with stage I–IV breast cancer that are scheduled to start a new course of 
chemotherapy in the neo-adjuvant, adjuvant or metastatic setting for newly diagnosed or 
recurrent disease were consented to participate in the study. For this manuscript, only neo-
adjuvant and adjuvant settings were analyzed. Patients with a history of clonal bone marrow 
disorder (e.g., acute or chronic leukemia), concurrent experimental therapy or prior or 
current HDAC inhibitor therapy were excluded. Patients received standard-of-care 
chemotherapy regimens including the use of growth factors. Medical history and treatment 
information were abstracted from the medical record. Patients were also consented to 
undergo phlebotomy prior to the beginning of treatment for molecular analyses. Molecular 
analyses were performed by investigators blinded to the patient data, and investigators 
collecting clinical information were blinded to laboratory results until data collection was 
complete.
Assessment of p16 expression
10 ml of blood was drawn into lavender (EDTA) tubes and used to isolate CD3+ T 
lymphocytes. Total RNA was isolated using RNeasy Mini Kit (Qiagen) and cDNA was 
prepared using ImProm-II reverse transcriptase kit (Promega). Expression of p16INK4a was 
measured by a TaqMan quantitative reverse-transcription polymerase chain reaction specific 
for p16INK4a and normalized to the YWHAZ housekeeping gene.
Statistical Analyses
An unpaired t test was used to calculate a P value for pairwise comparisons. P values on 
multiple comparisons were calculated using two-way ANOVA with Bonferroni post-test. 
Association between p16INK4a and grade 3/4 toxicities was performed using one-way 
analysis of variance. P values of .05 or less were considered statistically significant. 
Wilcoxon p values were used because of the small size of groups. Data were analyzed by A. 
M. Deal using SAS version 9.2 (SAS, Cary, NC) and STATA version 12 (StataCorp, College 
Station, TX).
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Simone Brandenburg for helping with the titration of doxorubicin in cell culture. We thank Herman Sillje 
for sharing the CD31 antibody.
This work was supported by grants from the American Italian Cancer Foundation (MD), and US National Institutes 
of Health (AG009909, AG017242, AG041122 and CA122023) (JC, DZ). JC and DZ are founders of Unity 
Biotechnology. MD, JC and DZ own equity in Unity Biotechnology. NM is an employee of HealtSpan Diagnostics. 
NES is a founder and has a financial interest in HealthSpan Diagnostics.
References
1. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013; 75:685–705. [PubMed: 
23140366] 
2. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related 
disease: from mechanisms to therapy. Nat Med. 2015; 21:1424–35. [PubMed: 26646499] 
3. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al. Clearance of 
p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature. 2011; 479:232–6. 
[PubMed: 22048312] 
4. Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, et al. Naturally occurring 
p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016; 530:184–9. [PubMed: 26840489] 
5. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, et al. Senescence-associated secretory 
phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. 
PLoS Biol. 2008; 6:2853–68. [PubMed: 19053174] 
6. Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer. 2008; 
113:1857–87. [PubMed: 18798529] 
7. Schunemann M, Anker SD, Rauchhaus M. Cancer fatigue syndrome reflects clinically non-overt 
heart failure: an approach towards onco-cardiology. Nat Clin Pract Oncol. 2008; 5:632–3. [PubMed: 
18813228] 
8. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, et al. Clinical 
ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 
309:2371–81. [PubMed: 23757085] 
9. Schmitt CA. Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer. 
2003; 3:286–95. [PubMed: 12671667] 
10. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the 
tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 
2012; 18:1359–68. [PubMed: 22863786] 
11. Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl 
Cancer Inst. 2010; 102:1536–46. [PubMed: 20858887] 
12. Sanoff HK, Deal AM, Krishnamurthy J, Torrice C, Dillon P, Sorrentino J, et al. Effect of cytotoxic 
chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst. 2014; 
106:dju057. [PubMed: 24681605] 
13. Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Durr P, et al. 
p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell. 2006; 5:379–
89. [PubMed: 16911562] 
14. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, et al. Ink4a/Arf 
expression is a biomarker of aging. J Clin Invest. 2004; 114:1299–307. [PubMed: 15520862] 
15. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for 
senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014; 31:722–
33. [PubMed: 25499914] 
Demaria et al. Page 14
Cancer Discov. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer 
and antibacterial drugs. Chem Biol. 2010; 17:421–33. [PubMed: 20534341] 
17. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Drug-induced histone 
eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat 
Commun. 2013; 4:1908. [PubMed: 23715267] 
18. Freund A, Laberge RM, Demaria M, Campisi J. Lamin B1 loss is a senescence-associated 
biomarker. Mol Biol Cell. 2012; 23:2066–75. [PubMed: 22496421] 
19. Davalos AR, Kawahara M, Malhotra GK, Schaum N, Huang J, Ved U, et al. p53-dependent release 
of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol. 2013; 201:613–29. 
[PubMed: 23649808] 
20. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA 
damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 
2009; 11:973–9. [PubMed: 19597488] 
21. van der Most RG, Currie AJ, Robinson BW, Lake RA. Decoding dangerous death: how cytotoxic 
chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 2008; 15:13–
20. [PubMed: 18007666] 
22. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339:900–5. 
[PubMed: 9744975] 
23. Fantozzi A, Christofori G. Mouse models of breast cancer metastasis. Breast Cancer Res. 2006; 
8:212. [PubMed: 16887003] 
24. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, et al. Clearance of senescent cells 
by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016; 22:78–83. 
[PubMed: 26657143] 
25. Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, et al. Cancer-related fatigue in 
patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin 
Study Group. Lancet Oncol. 2016; 17:1453–62. [PubMed: 27612583] 
26. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Ibrahim JG, et al. Expression of p16(INK4a) in 
peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009; 8:439–48. [PubMed: 
19485966] 
27. Wood WA, Krishnamurthy J, Mitin N, Torrice C, Parker JS, Snavely AC, et al. Chemotherapy and 
Stem Cell Transplantation Increase p16INK4a Expression, a Biomarker of T-cell Aging. 
EBioMedicine. 2016; 11:227–38. [PubMed: 27591832] 
28. Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, et al. Monitoring 
tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell. 2013; 152:340–
51. [PubMed: 23332765] 
29. Demaria M, Desprez PY, Campisi J, Velarde MC. Cell Autonomous and Non-Autonomous Effects 
of Senescent Cells in the Skin. J Invest Dermatol. 2015; 135:1722–6. [PubMed: 25855157] 
30. Dorr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Dabritz JH, et al. Synthetic lethal metabolic 
targeting of cellular senescence in cancer therapy. Nature. 2013; 501:421–5. [PubMed: 23945590] 
31. Beeharry N, Broccoli D. Telomere dynamics in response to chemotherapy. Curr Mol Med. 2005; 
5:187–96. [PubMed: 15974872] 
32. Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, et al. MTOR regulates the pro-
tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell 
Biol. 2015; 17:1049–61. [PubMed: 26147250] 
33. Flynn JM, O’Leary MN, Zambataro CA, Academia EC, Presley MP, Garrett BJ, et al. Late-life 
rapamycin treatment reverses age-related heart dysfunction. Aging Cell. 2013; 12:851–62. 
[PubMed: 23734717] 
Demaria et al. Page 15
Cancer Discov. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Statement of significance
Many genotoxic chemotherapies have debilitating side effects and also induce cellular 
senescence in normal tissues. The senescent cells remain chronically present where they 
can promote local and systemic inflammation that causes or exacerbates many side 
effects of the chemotherapy.
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Figure 1. Therapy-induced senescence of primary cells
(A) Mouse dermal fibroblasts (MDFs) were treated with 250 nM doxorubicin (Doxo) for 24 
hrs. 7 days later, cells were either fixed and stained for SA-β-gal or incubated for 24 hrs with 
EdU then fixed and stained. Shown is the percentage of positive cells (>100 cells scored). 
N=3 independent experiments. (B) Quantitative real-time PCR (qRT-PCR) analysis of RNA 
isolated from control- (DMSO) or Doxo- (250 nM) treated MDFs. RNA was analyzed for 
mRNAs encoding the indicated proteins relative to actin (to control for cDNA quantity). 
N=3 independent experiments. A.U.=arbitrary units. (C) Lamin B1 (LMNB1), HMGB1 and 
p21 protein levels were measured by immunoblotting using whole cell extracts from control- 
or Doxo-treated MDFs. Actin served as a loading control. (D) Immunofluorescence of 
control- or Doxo-treated cells. Blue, DAPI stained nuclei; green, 53BP1 immunostaining. 
(E) p16-3MR male mice, 10 d after treatment with the indicated concentrations of Doxo (0, 
2, 10, 25 mg/kg), were injected with coelentarazine and luminescence was quantified using 
the Xenogen Imaging system. (F) Representative images from E. N=4. (G) RNA was 
extracted from the skin, lung and liver of control- or Doxo- (10 mg/kg) treated mice, and 
quantified by qRT-PCR for mRNA encoding p16INK4a. mRNA encoding tubulin was used as 
a control. N=5. (H) Control- or Doxo- (10 mg/kg) treated female mice were injected with 
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coelentarazine, and luminescence quantified using the Xenogen Imaging system at the 
indicated times after Doxo treatment. N=4. Data are means ± SEMs. *p<0.05; **p<0.01; 
***p<0.001.
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Figure 2. Senescence-associated inflammation, bone marrow suppression and cardiac 
dysfunction
Control- or Doxo- (10 mg/kg) treated p16-3MR male mice were given vehicle (PBS) or 25 
mg/kg ganciclovir (GCV) for 5 days (daily i.p. injections). (A) Mice were injected with 
coelentarazine, and luminescence was monitored using the Xenogen Imaging system. (B) 
Quantitative real-time PCR (qRT-PCR) analysis of RNA isolated from lungs. mRNA levels 
encoding the indicated proteins were quantified relative to tubulin (control) mRNA. The 
dotted line indicates expression level in control mice, set at 1 for each protein. N=5. 
A.U.=arbitrary units. (C) Lungs were fixed in paraffin and stained for γH2AX. Blue, DAPI 
stained nuclei; green, γH2AX immunostaining. (D–E) IL-6 (D) and Cxcl-1 (E) levels in 
serum were quantified by ELISA. N=4. (F–H) Number of Colony Forming Unit-
Granulocyte, Monocyte (F), Colony Forming unit-Granulocyte, Erythrocyte, Monocyte, 
Megakaryocyte (G) and 2-week Cobblestone Area Forming Cells (H) in bone marrow cells 
(BMCs) harvested from mice 3 days after the last PBS or GCV injection, determined by 
Colony Forming Cell and Cobblestone Area Forming Cell assays, respectively. N=3. (I–K) 
Two-dimensional transthoracic echocardiography was performed in mice 4 weeks after 
Doxo treatment. Graphs show fractional shortening (I), ejection fraction (J) and heart beat 
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(K) measurements. N=10. bpm=beats per minute. Data are means ± SEMs. *p<0.05; 
**p<0.01; ***p<0.001.
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Figure 3. Senescence promotes tumor metastasis and relapse
(A–C) fLUC-MMTV-PyMT cells (105) were injected into the mammary fat pad of p16-3MR 
female mice and treated with PBS or Doxo (10 mg/kg). 7–10 days later, the animals were 
injected with PBS or 25 mg/kg GCV for 5 days (daily i.p. injections). (A) Mice were 
followed for survival. N=5. (B) 7, 14 and 21 days after cancer cell injections, Doxo-treated 
mice were given D-Luciferin and luminescence was measured using the Xenogen Imaging 
system. Luminescence identified fLUC-MMTV-PyMT cells. At 21 days, the number of mice 
with metastasis was evaluated based on luminescence of fLUC-MMTV-PyMT cells (C). (D–
G) fLUC-MMTV-PyMT cells (105) were injected into the mammary fat pad of p16-3MR 
mice. 10 days later, primary tumors were surgically removed and mice were treated with 
Doxo (10 mg/kg), then, 3 days later, with PBS or 25 mg/kg GCV for 5 days (daily i.p. 
injections). (D) Mice were given D-Luciferin and luminescence of the primary tumors was 
measured and quantified at the indicated time points using the Xenogen Imaging system. 
Luminescence identified fLUC-MMTV-PyMT cells. N=8. (E) 4 weeks after Doxo treatment, 
metastasis was evaluated based on luminescence signals from lungs, as described in D. N=8. 
(F–G) Lungs were excised and luminescence was measured to quantify the number of 
metastasis using the Xenogen Imaging system. N=6 for Doxo + PBS, N=3 for Doxo + GCV. 
Data are means ± SEMs. *p<0.05; **p<0.01; ***p<0.001.
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Figure 4. Effects of senescent cells on activity
Control- or Doxo- (10 mg/kg) treated p16-3MR female mice were treated with vehicle 
(PBS) or 25 mg/kg of ganciclovir (GCV) for 5 days (daily i.p. injections). (A) Mice were 
single-housed in metabolic cages and monitored for 4 consecutive days. Data are the average 
of 4 day and night cycles and show the percentage of time spent on the running wheel. N=8. 
(B) Running distance in meters, calculated from the number of revolutions of the running 
wheel, during the nocturnal cycles (average of 4). N=8. (C) Mice were single-housed in 
standard cages equipped with running wheels. The number of revolutions was determined 
before Doxo treatment and 12 days after Doxo treatment. For each mouse, values are from 
an average of 3 consecutive nights. The graph shows the ratio between the post- and pre-
treatment running distance, expressed as a percentage. N=10. (D) Mice described in C were 
monitored for how long they were capable of grasping a reversed cage grid. For each mouse, 
values are an average of 5 trials. The graph shows the ratio between the post- and pre-
treatment grasping time, expressed as a percentage. N=10. (E) Food intake of the mice 
described in A was measured during the night cycles. Data are means ± SEMs. *p<0.05; 
**p<0.01; ***p<0.001.
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